Michael Arbushites

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry Gómez, Zeba Aziz et al. · Journal of Clinical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez et al. · Journal of Clinical Oncology · 2008 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel‐Angel Perales, Mark A. Schroeder et al. · Blood · 2020 · 303 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +3

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

Michael F. Press, Richard S. Finn, David Cameron et al. · Clinical Cancer Research · 2008 · 173 citations

Medicine, Oncology, Pharmacology +16

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu et al. · Annals of Oncology · 2009 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16